Indicine N-oxide-d7 ((+)-Indicine N-oxide-d7) is the deuterium labeled Indicine N-oxide. Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research^[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

322.41

C₁₅H₁₈D₇NO₆

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. V M Whitehead, et al. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study. Cancer Chemother Pharmacol. 1990;26(5):377-9.

  [3]. J S Kovach, et al. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res. 1979 Nov;39(11):4540-4.

Indicine N-oxide-d7 ((+)-Indicine N-oxide-d7) is the deuterium labeled Indicine N-oxide. Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research^[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

322.41

C₁₅H₁₈D₇NO₆

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. V M Whitehead, et al. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study. Cancer Chemother Pharmacol. 1990;26(5):377-9.

  [3]. J S Kovach, et al. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res. 1979 Nov;39(11):4540-4.

Indicine N-oxide-d7 ((+)-Indicine N-oxide-d7) is the deuterium labeled Indicine N-oxide. Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research^[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

322.41

C₁₅H₁₈D₇NO₆

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. V M Whitehead, et al. Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study. Cancer Chemother Pharmacol. 1990;26(5):377-9.

  [3]. J S Kovach, et al. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res. 1979 Nov;39(11):4540-4.